Modafinil Augmentation Therapy in Unipolar and Bipolar Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
The DOI matches its Crossref record, with a small difference in title or year; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Current pharmacologic treatments for a depressive episode in unipolar major depressive disorder (MDD) and bipolar depression are limited by low rates of remission. Residual symptoms include a persistent low mood and neurovegetative symptoms such as fatigue. The objective of this study was to examine the efficacy and tolerability of augmentation of first-line therapies with the novel stimulant-like agent modafinil in MDD and bipolar depression. DATA SOURCES: MEDLINE/PubMed, PsycINFO, 1980-April 2013 were searched using the following terms: (modafinil or armodafinil) and (depressi* or depressed or major depressive disorder or major depression or unipolar or bipolar or dysthymi*). Inclusion criteria were as follows: randomized controlled trial (RCT) design, sample comprising adult patients (18-65 years) with unipolar or bipolar depression, diagnosis according to DSM-IV, ICD-10, or other well-recognized criteria, modafinil or armodafinil given as augmentation therapy in at least 1 arm of the trial, and publication in English in a peer-reviewed journal. STUDY SELECTION: Double-blind, randomized, placebo-controlled clinical trials of adjunctive treatment with modafinil or armodafinil of standard treatment for depressive episodes in MDD and bipolar depression were selected. DATA EXTRACTION: Two independent appraisers assessed the eligibility of the trials. A random-effects meta-analysis with DerSimonian-Laird method was used. Moderator effects were evaluated by meta-regression. RESULTS: Data from 6 RCTs, with a total of 910 patients with MDD or bipolar depression, consisting of 4 MDD RCTs (n = 568) and 2 bipolar depression RCTs (n = 342) were analyzed. The meta-analysis revealed significant effects of modafinil on improvements in overall depression scores (point estimate = -0.35; 95% CI, -0.61 to -0.10) and remission rates (odds ratio = 1.61; 95% CI, 1.04 to 2.49). The treatment effects were evident in both MDD and bipolar depression, with no difference between disorders. Modafinil showed a significant positive effect on fatigue symptoms (95% CI, -0.42 to -0.05). The adverse events were no different from placebo. CONCLUSIONS: Modafinil is an effective augmentation strategy for acute depressive episodes, including for symptoms of fatigue, in both unipolar and bipolar disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical guidelines such as CANMAT suggest caution regarding the use of stimulant and stimulant like molecules and based on previous meta-analysis (Goss et al., 2013; Kennedy et al., 2016) recommend their utilization as second-third line adjunctive agents.”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Goss et al., 2013
Citations
Cites
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., & Wang, P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091379 · Cited by 7,067
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Hirschfeld, R. M. A., Lewis, L., & Vornik, L. A. (2003) · PubMed · Cited by 943
Hirschfeld, R. M. A., Lewis, L., & Vornik, L. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0209 · Cited by 922
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713
Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior
Morris, S. E., & Cuthbert, B. N. (2012) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2012.14.1/smorris · Cited by 638
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Beddington, J., Cooper, C. L., Field, J., Goswami, U., Huppert, F. A., Jenkins, R., Jones, H. S., Kirkwood, T. B. L., Sahakian, B. J., & Thomas, S. M. (2008) · Nature · doi:10.1038/4551057a · Cited by 554
Self-citationCognitive Mechanisms of Treatment in Depression
Roiser, J. P., Elliott, R., & Sahakian, B. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.183 · Cited by 535
Self-citationFu, C. H. Y., Mourao-Miranda, J., Costafreda, S. G., Khanna, A., Marquand, A. F., Williams, S. C. R., & Brammer, M. J. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.020 · Cited by 337
Self-citationAntidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Judd, L. L., Schettler, P. J., Akiskal, H. S., Coryell, W., Leon, A. C., Maser, J. D., & Solomon, D. A. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.386 · Cited by 251
A Placebo-Controlled Evaluation of Adjunctive Modafinil in the Treatment of Bipolar Depression
Frye, M. A., Grunze, H., Suppes, T., McElroy, S. L., Keck, P. E., Walden, J., Leverich, G. S., Altshuler, L. L., Nakelsky, S., Hwang, S., et al. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06060981 · Cited by 249
Tylee, A., Gastpar, M., Lépine, J. P., & Mendlewicz, J. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199905002-00001 · Cited by 221
Fava, M., Thase, M. E., & DeBattista, C. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0112 · Cited by 207
Modafinil Augmentation of Antidepressant Treatment in Depression
Menza, M. A., Kaufman, K. R., & Castellanos, A. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0510 · Cited by 202
DeBattista, C., Doghramji, K., Menza, M. A., Rosenthal, M. H., Fieve, R. R., & Modafinil in Depression Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0911 · Cited by 189
Walsh, N. D., Williams, S. C. R., Brammer, M. J., Bullmore, E. T., Kim, J., Suckling, J., Mitterschiffthaler, M. T., Cleare, A. J., Pich, E. M., Mehta, M. A., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.022 · Cited by 161
Self-citationPsychostimulants for depression
Candy, B., Jones, L., Williams, R., Tookman, A., & King, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006722.pub2 · Cited by 156
A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression
DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., & Poirier, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104910.75206.b9 · Cited by 144
Müller, U., Rowe, J. B., Rittman, T., Lewis, C., Robbins, T. W., & Sahakian, B. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.009 · Cited by 142
Self-citationNeuroanatomy of verbal working memory as a diagnostic biomarker for depression
Marquand, A. F., Mourão-Miranda, J., Brammer, M. J., Cleare, A. J., & Fu, C. H. Y. (2008) · NeuroReport · doi:10.1097/wnr.0b013e328310425e · Cited by 125
Self-citationProdromal and residual symptoms in bipolar I disorder
Keitner, G. I., Solomon, D. A., Ryan, C. E., Miller, I. W., Mallinger, A. G., Kupfer, D. J., & Frank, E. (1996) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(96)90018-8 · Cited by 124
Ravindran, A. V., Kennedy, S. H., O'Donovan, M. C., Fallu, A., Camacho, F., & Binder, C. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0112 · Cited by 119
Calabrese, J. R., Ketter, T. A., Youakim, J. M., Tiller, J. M., Yang, R., & Frye, M. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05900gry · Cited by 116
Fava, M., Thase, M. E., DeBattista, C., Doghramji, K., Arora, S., & Hughes, R. J. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701464858 · Cited by 109
Hypersomnia in inter-episode bipolar disorder: Does it have prognostic significance?
Kaplan, K. A., Gruber, J., Eidelman, P., Talbot, L. S., & Harvey, A. G. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.013 · Cited by 106
Effects of modafinil on cognitive functions in first episode psychosis
Scoriels, L., Barnett, J. H., Soma, P. K., Sahakian, B. J., & Jones, P. B. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2472-4 · Cited by 77
Self-citationAction of Modafinil Through Histaminergic and Orexinergic Neurons
Ishizuka, T., Murotani, T., & Yamatodani, A. (2012) · Vitamins and hormones · doi:10.1016/b978-0-12-394623-2.00014-7 · Cited by 65
Thase, M. E., Fava, M., DeBattista, C., Arora, S., & Hughes, R. J. (2006) · CNS Spectrums · doi:10.1017/s1092852900010622 · Cited by 61
Abolfazli, R., Hosseini, M., Ghanizadeh, A., Ghaleiha, A., Tabrizi, M., Raznahan, M., Golalizadeh, M., & Akhondzadeh, S. (2011) · Depression and Anxiety · doi:10.1002/da.20801 · Cited by 60
Dunlop, B. W., Crits-Christoph, P., Evans, D. L., Hirschowitz, J., Solvason, H. B., Rickels, K., Garlow, S. J., Gallop, R. J., & Ninan, P. T. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815abefb · Cited by 56
Use of bupropion with SRIs and venlafaxine
Spier, S. A. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:2<73::aid-da4>3.0.co;2-6 · Cited by 53
Psychostimulant augmentation of second generation antidepressants: A case series
Masand, P. S., Anand, V. S., & Tanquary, J. F. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:2<89::aid-da8>3.0.co;2-0 · Cited by 53
Gwirtsman, H. E., Szuba, M. P., Toren, L., & Feist, M. (1994) · PubMed · Cited by 40
Maurice-Tison, S., Verdoux, H., Gay, B., Perez, P., Salamon, R., & Bourgeois, M.-L. (1998) · Europe PMC (PubMed Central) · Cited by 37
Modafinil for Remitted Bipolar Depression with Hypersomnia
Fernandes, P. P., & Petty, F. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d226 · Cited by 32
Use of adjunctive stimulants in adult bipolar depression
Dell'Osso, B., & Ketter, T. A. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000326 · Cited by 31
Konuk, N., Atasoy, N., Atik, L., & Akay, Ö. (2006) · Advances in Therapy · doi:10.1007/bf02850053 · Cited by 11
Cited by
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
“In bipolar depression (and unipolar disorder) there is very limited evidence for efficacy (Goss et al., 2013).”
Self-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
“A meta-analysis of modafanil, an atypical stimulant, in MDD identified 4 trials (N 1⁄4 568), but only 2 (N 1⁄4 211) were adjunctive studies.(121) After excluding an outlier study, there was only marginal evidence for efficacy in modafinil-treated patients compared to placebo on both response and remission rates.”
BackgroundMethodCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“35) (Goss et al., 2013).”
Ashok, A. H., Marques, T. R., Jauhar, S., Nour, M. M., Goodwin, G. M., Young, A. H., & Howes, O. D. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.16 · Cited by 546
Inflammation in Depression and the Potential for Anti-Inflammatory Treatment
Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113700 · Cited by 516
“Finally, another emerging drug is the anti-epileptic drug modafinil, which has been associated with anti-inflammatory properties [56] and furthermore shown effective antidepressant effects in augmentation strategies for acute depressive episodes, including symptoms of fatigue, in both unipolar and bipolar disorders [6…”
Background
Metadata
- Authors
- Goss, A. J., Kaser, M., Costafreda, S. G., Sahakian, B. J., & Fu, C. H. Y.
- Corresponding author
- Fu, Cynthia H. Y.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2013-11-15
- Volume
- 74
- Issue
- 11
- Pages
- 1101-1107
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2020924268
- Cited by
- 133
- References
- 37
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 11 · 2023: 9 · 2022: 13 · 2021: 13 · 2020: 11 · 2019: 9 · 2018: 8 · 2017: 12 · 2016: 13 · 2015: 20 · 2014: 6
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust (089589/Z/09/Z, 093875/Z/10/Z, 093875)
- National Institute for Health and Care Research (CL-2011-17-003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- armodafinil, augmentation therapy, unipolar major depression, bipolar depression, remission rate, fatigue, adverse events, tolerability, adjunctive therapy, antidepressant efficacy, neurovegetative symptoms, residual depressive symptoms, treatment-resistant depression, mood stabilizers, lithium, valproic acid, atypical antipsychotics, antidepressants
- MeSH terms
- Modafinil, Antidepressive Agents, Benzhydryl Compounds, Bipolar Disorder, Major Depressive Disorder, Drug Therapy, Combination, Humans, Personality Inventory, Psychometrics, Randomized Controlled Trials as Topic, Antimanic Agents, Wakefulness-Promoting Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.